{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Hyponatremia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Dehydration"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Dyspnea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Pneumonia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Thrombocytopenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Febrile neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Tachycardia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Syncope"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Fluid retention"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Mucositis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hyperglycemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Constipation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Anorexia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Vomiting"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Other non-hematologic toxicity"}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Toxicity as the total number of participants with a given grade 3 and/or grade 4 adverse event","groups":[{"description":"Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.","id":"OG000","title":"Gemcitabine, Docetaxel"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Every 2 weeks","title":"Toxicity as Measured by Number and Grade of Adverse Events","type":"SECONDARY","unitOfMeasure":"participants"}